What is the starting dose of semaglutide (GLP-1 receptor agonist) for a patient with type 2 diabetes mellitus (T2DM) and a hemoglobin A1c (HbA1c) level of 7.0%, likely already on metformin (biguanide)?

Starting Dose of Semaglutide

When adding semaglutide to a patient's regimen, start at 0.25 mg subcutaneously once weekly, then increase to 0.5 mg once weekly after 4 weeks. 1

Initial Dosing Protocol

• The FDA-approved starting dose is 0.25 mg once weekly for the first 4 weeks, which serves as a dose-escalation period rather than a therapeutic dose 1
• After the initial 4-week period, increase to 0.5 mg once weekly, which represents the first therapeutic maintenance dose 1
• If additional glycemic control is needed after at least 4 weeks at 0.5 mg, the dose can be further increased to 1.0 mg once weekly 1

Administration Details

• Administer once weekly at any time of day, with or without meals 1
• Inject subcutaneously in the abdomen, thigh, or upper arm 1
• If a dose is missed, administer within 5 days of the missed dose 1

Clinical Context for This Patient

For a patient with T2DM and HbA1c of 7.0% already on metformin, adding semaglutide is strongly recommended based on current guidelines 2:

• GLP-1 agonists like semaglutide reduce all-cause mortality, major adverse cardiovascular events (MACE), and stroke when added to metformin 2
• The American College of Physicians provides strong recommendation with high-certainty evidence for adding GLP-1 agonists to metformin in patients with inadequate glycemic control 2

Expected Outcomes with Standard Dosing

• At the 0.5 mg dose, expect HbA1c reduction of approximately 1.2% from baseline 3
• At the 1.0 mg dose, expect HbA1c reduction of approximately 1.6-1.9% from baseline 4, 3
• Weight loss of 3.5-5.2 kg can be expected depending on the final maintenance dose achieved 3

Higher Dose Option for Inadequate Response

• If the patient does not achieve adequate glycemic control on 1.0 mg weekly, a 2.0 mg weekly dose is available as a treatment intensification option 4
• The 2.0 mg dose provides an additional 0.23 percentage point reduction in HbA1c compared to 1.0 mg, with similar safety profile 4

Common Pitfalls to Avoid

• Never skip the initial 0.25 mg dose-escalation phase, as this significantly increases gastrointestinal side effects, which are the most common reason for treatment discontinuation 1, 3
• Do not advance dosing faster than every 4 weeks, as premature escalation increases nausea and vomiting rates 1
• If the patient is on a sulfonylurea, consider reducing or discontinuing it when adding semaglutide to minimize hypoglycemia risk, as GLP-1 agonists have glucose-dependent insulin secretion 2